CFA
CYTK icon

Camarda Financial Advisors’s Cytokinetics CYTK Stock Holding History

Camarda Financial Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,217
Closed -$205K – 68
2022
Q2 		$205K Buy
+5,217
New +$210K 0.2% 68

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Camarda Financial Advisors's CYTK Position: Q3 2022 in Review

Camarda Financial Advisors sold out of Cytokinetics (CYTK) in Q3 2022, closing a stake of 5,217 shares — an estimated $205K sold.

Camarda Financial Advisors first reported a position in CYTK in Q2 2022 and held it in 1 quarter. The position peaked at $205K in Q2 2022. 277 funds tracked by Wall St. Rank hold CYTK as of Q3 2022.

  • Camarda Financial Advisors reported no remaining Cytokinetics position as of Q3 2022 after selling out during the quarter.
  • Camarda Financial Advisors sold 5,217 Cytokinetics shares in Q3 2022, an estimated $205K.
  • Camarda Financial Advisors first reported a position in Cytokinetics in Q2 2022 and held it in 1 quarter.
  • Camarda Financial Advisors's Cytokinetics position peaked at $205K in Q2 2022.
  • 277 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2022.

Based on Camarda Financial Advisors's 13F filing for Q3 2022, filed 7 Nov 2022.